Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Author Biographies
D.B. Bernard
Haematology Clinic, Johannesburg General Hospital and Department of Medicine, University of the Witwatersrand, Johannesburg
S.R. Lynch
Haematology Clinic, Johannesburg General Hospital and Department of Medicine, University of the Witwatersrand, Johannesburg
T.H. Bothwell
Haematology Clinic, Johannesburg General Hospital and Department of Medicine, University of the Witwatersrand, Johannesburg
W.R. Bezwoda
Haematology Clinic, Johannesburg General Hospital and Department of Medicine, University of the Witwatersrand, Johannesburg
K. Stevens
Departments of Chemical Pathology and Haematology, School of Pathology, South African Institute for Medical Research, and the University of the Witwatersrand, Johannesburg
G. Shulman
Departments of Chemical Pathology and Haematology, School of Pathology, South African Institute for Medical Research, and the University of the Witwatersrand, Johannesburg
Main Article Content
Multiple Myeloma
D.B. Bernard
S.R. Lynch
T.H. Bothwell
W.R. Bezwoda
K. Stevens
G. Shulman
Abstract
The results of the use of melphalan in 52 patients with multiple myeloma have been analysed. The median survival of the whole group of patients was 30 months, and of those with renal insufficiency only 12,5 months. Bence-lones proteinuria was also a poor prognostic finding,. but only because of its association with renal failure. Patients with Bence-Jones proteinuria and normal renal function had a median survival of 41 months. Responsiveness to therapy by criteria based on those of the Chronic Leukemial Multiple Myeloma Task Force could be assessed in 25 patients. Dramatic symptomatic relief occurred in all but one of the responsive patients, but in only one-fifth of those who did not respond to therapy.
S. Afr. Med. J., 48, 1026 (1974).
Donate
AJOL is a Non Profit Organisation that cannot function without donations.
AJOL and the millions of African and international researchers who rely on our free services are deeply grateful for your contribution.
AJOL is annually audited and was also independently assessed in 2019 by E&Y.
Your donation is guaranteed to directly contribute to Africans sharing their research output with a global readership.
Once off donations here:
For annual AJOL Supporter contributions, please view our Supporters page.
Tell us what you think and showcase the impact of your research!
Please take 5 minutes to contribute to our survey so that we can better understand the contribution that African research makes to global and African development challenges. Share your feedback to help us make sure that AJOL's services support and amplify the voices of researchers like you.